Previous 10 | Next 10 |
2024-02-14 17:35:57 ET Summary Novo Nordisk reported great results for fiscal 2023 with the top and bottom line growing in the higher double-digits. Growth was especially driven by Wegovy and Ozempic, and management is also optimistic for fiscal 2024. Novo Nordisk is trading f...
2024-02-14 02:59:00 ET Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) ....
2024-02-13 23:21:35 ET Summary Eli Lilly's stock is overvalued by around 27% despite its success in developing drugs for diabetes and obesity. LLY has strong financial performance with steady revenue growth and profitability expansion. The success of its drugs Mounjaro and Zep...
2024-02-13 17:22:43 ET Summary The S&P 500 Index is up 5.5% in 2024, led by mega-cap tech stocks, while small caps are down slightly. Large caps' Q4 earnings beat rate is 72% with 50% of firms beating on the top line, cementing an end to last year's earnings recession. The...
2024-02-13 15:50:11 ET Summary AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships. Analyst firms continue to Buy/Outperform ratings on the stock, but the company's p...
2024-02-13 13:07:35 ET More on Eli Lilly Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript Federal judge...
2024-02-13 05:50:00 ET Weight-loss drugs are hot. Just look at the recent performances of Eli Lilly (NYSE: LLY) , which won U.S. approval in November for Zepbound, and Novo Nordisk (NYSE: NVO) , which markets Ozempic and Wegovy. Lilly's share price has soared more than 115% ...
2024-02-13 00:50:00 ET Summary Let's take a look at the landscape for GLP-1 drug development (including the drugs that target associated hormones). Novo Nordisk has had a spectacular success with semaglutide (Ozempic/Wegovy), and its effects on weight loss have been established to...
2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...
2024-02-12 10:32:46 ET More on Coca-Cola Stocks To Watch: Spotlight On Coca-Cola, Coinbase, Shopify And Cisco Coca-Cola: IRS Claim - A Matter Of Risk And Consequence Coca-Cola: A Dominant Force With High Upside Earnings week ahead: Coca-Cola, Cisco, Shopify, ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 09:20:00 ET While the market for anti-obesity medicines is characterized today by a fight between Novo Nordisk 's (NYSE: NVO) drug Wegovy and Eli Lilly 's (NYSE: LLY) drug Zepbound, that won't always be the case. Over the coming years, the competitive dynamics of ...
2024-07-29 07:30:00 ET When a major player announces good news in a lucrative market like weight loss drugs, it's often enough to drive shares of competitors down based on the assumption that they will have struggles ahead. That's just what happened after an announcement by Roche Hold...
2024-07-27 07:15:00 ET According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't. Equities that can perform well throughout bull runs might be good to ...